Povorcitinib for Vitiligo
Trial Summary
What is the purpose of this trial?
This trial is testing a medication called povorcitinib to see if it can help people with nonsegmental vitiligo, a condition where skin loses its color in patches. The medication might work by stopping the immune system from attacking the cells that give skin its color. Researchers want to find out if it is effective and safe for these patients.
Will I have to stop taking my current medications?
The trial requires participants to stop using any treatments specifically for vitiligo from the screening through the final safety follow-up visit. It does not specify about other medications, so you may need to discuss this with the trial team.
What data supports the effectiveness of the drug Povorcitinib for treating vitiligo?
How is the drug Povorcitinib different from other vitiligo treatments?
Povorcitinib is a Janus kinase (JAK) inhibitor, similar to other treatments like tofacitinib and ruxolitinib, which have shown effectiveness in treating vitiligo by targeting the immune system to help repigment the skin. What makes Povorcitinib unique is its specific formulation and potential effectiveness, as it is being studied in clinical trials specifically for vitiligo, whereas other JAK inhibitors have been used off-label or in combination with other therapies.12346
Research Team
Incyte Medical Monitor
Principal Investigator
Incyte Corporation
Eligibility Criteria
This trial is for adults over 18 with nonsegmental vitiligo, which causes loss of skin color in blotches. Participants should have a certain level of skin involvement and agree to stop other vitiligo treatments during the study. They must also take precautions to prevent pregnancy or avoid fathering children.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Povorcitinib Dose A or placebo for 52 weeks
Extension
Participants who received placebo switch to Povorcitinib Dose A for an additional 52 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Povorcitinib
Find a Clinic Near You
Who Is Running the Clinical Trial?
Incyte Corporation
Lead Sponsor
Steven Stein
Incyte Corporation
Chief Medical Officer since 2015
MD from University of Witwatersrand
Hervé Hoppenot
Incyte Corporation
Chief Executive Officer since 2014
MBA from ESSEC Business School